Prescription medication · PTHrP Analog
abaloparatide
Also sold as Tymlos. Tymlos treats osteoporosis in women after menopause and in men.
Data updated 2026-05-15
- 24,667
- FDA reportsModerately reported
- $1646.36
- Brand price (NADAC)
abaloparatide (Tymlos) is a prescription PTHrP Analog. Tymlos treats osteoporosis in women after menopause and in men.
Tymlos is a medicine to treat osteoporosis. It helps make your bones stronger and less likely to break.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$1646.36/unit
Generic Available
No
RADIUS
Pricing data from NADAC (CMS), effective January 1, 2024. Compare all drug costs →
What it does
Tymlos treats osteoporosis in women after menopause and in men.
Common side effects
High calcium in your urine, Feeling dizzy, Feeling sick to your stomach
Key warnings
Tymlos may increase the risk of bone cancer (osteosarcoma).
The sections below are summarized in plain English from abaloparatide's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Tymlos is similar to a natural hormone in your body. It helps your body build new bone. This makes your bones stronger and less likely to break.
Side Effects (from patient reports)
Based on 24,667 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for abaloparatide, by number of reports
- Headache
Headache
4,180 reports
- Nausea
Nausea
3,222 reports
- Dizziness
Dizziness
3,122 reports
- Fatigue
Fatigue
2,742 reports
- Heart Rate Increased
Heart Rate Increased
2,139 reports
- Arthralgia
Arthralgia
1,802 reports
- Palpitations
Palpitations
1,785 reports
- Bone Pain 1,414
Bone Pain
1,414 reports
- Back Pain 1,289
Back Pain
1,289 reports
- Pain 1,269
Pain
1,269 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for abaloparatide each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where abaloparatide sits
abaloparatide has more FDA adverse-event reports than 60% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is abaloparatide; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 24,667 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2015–2025.
Total Reports
24,667
Reports Mentioning Death
266
1.1% of reports — not proof of cause
Hospitalization Reports
1,677
Top Indication
Osteoporosis Postmenopausal
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | HEADACHE | 4,180 |
| 2 | NAUSEA | 3,222 |
| 3 | DIZZINESS | 3,122 |
| 4 | FATIGUE | 2,742 |
| 5 | HEART RATE INCREASED | 2,139 |
| 6 | ARTHRALGIA | 1,802 |
| 7 | PALPITATIONS | 1,785 |
| 8 | BONE PAIN | 1,414 |
| 9 | BACK PAIN | 1,289 |
| 10 | PAIN | 1,269 |
| 12 | INJECTION SITE BRUISING | 976 |
| 13 | PAIN IN EXTREMITY | 958 |
| 14 | PRODUCT DOSE OMISSION | 940 |
| 15 | PRODUCT QUALITY ISSUE | 914 |
| 16 | LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES | 857 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Tymlos may increase the risk of bone cancer (osteosarcoma). You should not take this medicine if you have certain conditions that increase this risk. These include Paget's disease, bone cancer, radiation treatment to your bones, or certain hereditary disorders. If you have symptoms of feeling dizzy, palpitations, tachycardia, or nausea, you should sit or lie down.
Common Questions
How long can I use Tymlos?
What if I have kidney problems?
Can Tymlos cause low blood pressure?
What should I do if I feel dizzy after taking Tymlos?
Can Tymlos cause high calcium levels?
What if I have a history of kidney stones?
How should I dispose of the Tymlos pen?
What does Tymlos look like?
What if the Tymlos solution has particles or is discolored?
What are the common side effects of abaloparatide?
What drug class is abaloparatide?
What pregnancy or breastfeeding source fields are listed for abaloparatide?
Related Medications in PTHrP Analog
Other drugs grouped near abaloparatide - same-class peers and common alternatives.
alendronate
Fosamax
Binosto is a medicine that helps make your bones stronger.
Compare with abaloparatide →
calcitonin
Miacalcin, Fortical
Calcitonin is a medicine that helps manage calcium levels in your body.
Compare with abaloparatide →
denosumab
Prolia, Xgeva
Stoboclo is a medicine that helps to treat osteoporosis and increase bone mass.
Compare with abaloparatide →
ibandronate
Boniva
Ibandronate (Boniva) is a medicine that helps treat and prevent bone loss in women after menopause.
Compare with abaloparatide →
risedronate
Actonel
Risedronate sodium delayed-release tablets help treat osteoporosis after menopause.
Compare with abaloparatide →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for abaloparatide: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 24,667.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 1.08%.
- varenicline Δ 0.05 pts · 5,766 reports · Nicotinic Receptor Partial Agonist 1.13%death share
- minoxidil Δ 0.06 pts · 43,650 reports · Vasodilator 1.01%death share
- ertugliflozin Δ 0.08 pts · 1,037 reports · SGLT2 Inhibitor 1.16%death share
- evolocumab Δ 0.11 pts · 155,068 reports · PCSK9 Inhibitor 1.19%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on abaloparatide
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for abaloparatide
The FDA label for abaloparatide (sold under brand names such as Tymlos) classifies it as a prescription-only medication in the PTHrP Analog class. Tymlos treats osteoporosis in women after menopause and in men. Official labeling lists 16 commonly reported side effects, including High calcium in your urine, Feeling dizzy, Feeling sick to your stomach.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 24,667 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: April 4, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages